151 related articles for article (PubMed ID: 11216672)
1. Schedule-dependent interaction between raltitrexed and 5-fluorouracil in human colon cancer cell lines in vitro.
Kano Y; Akutsu M; Suzuki K; Yazawa Y; Tsunoda S; Furukawa Y
Oncol Res; 2000; 12(3):137-48. PubMed ID: 11216672
[TBL] [Abstract][Full Text] [Related]
2. Schedule-dependent synergism and antagonism between raltitrexed ("Tomudex") and methotrexate in human colon cancer cell lines in vitro.
Kano Y; Akutsu M; Tsunoda S; Suzuki K; Yazawa Y; Furukawa Y
Jpn J Cancer Res; 2001 Jan; 92(1):74-82. PubMed ID: 11173547
[TBL] [Abstract][Full Text] [Related]
3. Schedule-dependent interactions between raltitrexed and cisplatin in human carcinoma cell lines in vitro.
Kano Y; Akutsu M; Suzuki K; Yazawa Y; Tsunoda S
Jpn J Cancer Res; 2000 Apr; 91(4):424-32. PubMed ID: 10804291
[TBL] [Abstract][Full Text] [Related]
4. Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro.
Kano Y; Akutsu M; Tsunoda S; Ando J; Matsui J; Suzuki K; Ikeda T; Inoue Y; Adachi K
Br J Cancer; 1996 Sep; 74(5):704-10. PubMed ID: 8795571
[TBL] [Abstract][Full Text] [Related]
5. Combination studies of antifolates with 5-fluorouracil in colon cancer cell lines.
van der Wilt CL; Kuiper CM; Peters GJ
Oncol Res; 1999; 11(8):383-91. PubMed ID: 10803742
[TBL] [Abstract][Full Text] [Related]
6. Molecular downstream events and induction of thymidylate synthase in mutant and wild-type p53 colon cancer cell lines after treatment with 5-fluorouracil and the thymidylate synthase inhibitor raltitrexed.
Peters GJ; van Triest B; Backus HH; Kuiper CM; van der Wilt CL; Pinedo HM
Eur J Cancer; 2000 May; 36(7):916-24. PubMed ID: 10785598
[TBL] [Abstract][Full Text] [Related]
7. Combination of raltitrexed with other cytotoxic agents: rationale and preclinical observations.
Jackman AL; Kimbell R; Ford HE
Eur J Cancer; 1999 Mar; 35 Suppl 1():S3-8. PubMed ID: 10645207
[TBL] [Abstract][Full Text] [Related]
8. Synergistic antitumour effect of raltitrexed and 5-fluorouracil plus folinic acid combination in human cancer cells.
Avallone A; Di Gennaro E; Bruzzese F; Laus G; Delrio P; Caraglia M; Pepe S; Comella P; Budillon A
Anticancer Drugs; 2007 Aug; 18(7):781-91. PubMed ID: 17581300
[TBL] [Abstract][Full Text] [Related]
9. Schedule-dependent synergism and antagonism between paclitaxel and methotrexate in human carcinoma cell lines.
Kano Y; Akutsu M; Tsunoda S; Furuta M; Yazawa Y; Ando J
Oncol Res; 1998; 10(7):347-54. PubMed ID: 10063968
[TBL] [Abstract][Full Text] [Related]
10. Schedule-dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro.
Aschele C; Baldo C; Sobrero AF; Debernardis D; Bornmann WG; Bertino JR
Clin Cancer Res; 1998 May; 4(5):1323-30. PubMed ID: 9607593
[TBL] [Abstract][Full Text] [Related]
11. Schedule-dependent interactions between vinorelbine and paclitaxel in human carcinoma cell lines in vitro.
Kano Y; Akutsu M; Suzuki K; Ando J; Tsunoda S
Breast Cancer Res Treat; 1999 Jul; 56(1):79-90. PubMed ID: 10517345
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of sequential raltitrexed followed by bolus 5-fluorouracil in patients with advanced colorectal cancer.
Schwartz GK; Bertino J; Kemeny N; Saltz L; Kelsen DK; Tong W; Welch M; Endres S; Dimery I
Anticancer Drugs; 2004 Mar; 15(3):219-27. PubMed ID: 15014354
[TBL] [Abstract][Full Text] [Related]
13. Raltitrexed (Tomudex) in combination with 5-fluorouracil for the treatment of patients with advanced colorectal cancer: preliminary results from phase I clinical trials.
Schwartz GK; Harstrick A; González Barón M
Eur J Cancer; 1999 Mar; 35 Suppl 1():S9-13. PubMed ID: 10645208
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase II randomized study.
Caponigro F; Rosati G; De Rosa P; Avallone A; De Rosa V; De Lucia L; Comella P; Comella G
Oncology; 2002; 63(3):232-8. PubMed ID: 12381902
[TBL] [Abstract][Full Text] [Related]
15. Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells.
Sobrero AF; Aschele C; Guglielmi AP; Mori AM; Melioli GG; Rosso R; Bertino JR
J Natl Cancer Inst; 1993 Dec; 85(23):1937-44. PubMed ID: 8230285
[TBL] [Abstract][Full Text] [Related]
16. Raltitrexed/5-fluorouracil-based combination chemotherapy regimens in anticancer therapy.
Caponigro F; Avallone A; Budillon A; Comella P; Comella G
Anticancer Drugs; 2001 Jul; 12(6):489-97. PubMed ID: 11459994
[TBL] [Abstract][Full Text] [Related]
17. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.
Cocconi G; Cunningham D; Van Cutsem E; Francois E; Gustavsson B; van Hazel G; Kerr D; Possinger K; Hietschold SM
J Clin Oncol; 1998 Sep; 16(9):2943-52. PubMed ID: 9738562
[TBL] [Abstract][Full Text] [Related]
18. In vitro schedule-dependent interaction between paclitaxel and cisplatin in human carcinoma cell lines.
Kano Y; Akutsu M; Tsunoda S; Suzuki K; Yazawa Y
Cancer Chemother Pharmacol; 1996; 37(6):525-30. PubMed ID: 8612305
[TBL] [Abstract][Full Text] [Related]
19. Mature results from three large controlled studies with raltitrexed ('Tomudex').
Cunningham D
Br J Cancer; 1998; 77 Suppl 2(Suppl 2):15-21. PubMed ID: 9579851
[TBL] [Abstract][Full Text] [Related]
20. Combination of 5-fluorouracil and irinotecan on modulation of thymidylate synthase and topoisomerase I expression and cell cycle regulation in human colon cancer LoVo cells: clinical relevance.
Xu JM; Azzariti A; Tommasi S; Lacalamita R; Colucci G; Johnston PG; Church SW; Paradiso A
Clin Colorectal Cancer; 2002 Nov; 2(3):182-8. PubMed ID: 12482336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
